Arvinas touts healthy volunteer data for Parkinson's disease PROTAC

Max Gelman

Senior Editor

Arvinas reported early-stage data for its PROTAC program in healthy volunteers, hoping the results will eventually translate to patients with Parkinson’s disease.

The data, which …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Arvinas touts healthy volunteer data for Parkinson's disease PROTAC

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump administration leaves obesity coverage expansion out of new Medicare rule

Marks was asked to provide non-existent vaccine risk data: WSJ

Novavax’s held-up approval package may signal warning for Covid vaccine makers

Kennedy team defends Marks firing, while 20% of staff cuts may be 'mistakes'

Secretive Chinese startup begins first-ever clinical trial of circular RNA therapy

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Arv­inas touts healthy vol­un­teer da­ta for Parkin­son's dis­ease PRO­TAC

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump ad­min­is­tra­tion leaves obe­si­ty cov­er­age ex­pan­sion out of new Medicare rule

Marks was asked to pro­vide non-ex­is­tent vac­cine risk da­ta: WSJ

No­vavax’s held-up ap­proval pack­age may sig­nal warn­ing for Covid vac­cine mak­ers

Kennedy team de­fends Marks fir­ing, while 20% of staff cuts may be 'mis­takes'

Se­cre­tive Chi­nese start­up be­gins first-ever clin­i­cal tri­al of cir­cu­lar RNA ther­a­py

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

Arvinas touts healthy volunteer data for Parkinson's disease PROTAC

Trump administration leaves obesity coverage expansion out of new Medicare rule

Marks was asked to provide non-existent vaccine risk data: WSJ

Novavax’s held-up approval package may signal warning for Covid vaccine makers

Kennedy team defends Marks firing, while 20% of staff cuts may be 'mistakes'

Secretive Chinese startup begins first-ever clinical trial of circular RNA therapy

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO